Group cognitive behaviour therapy for intimate partner violence (IPV) perpetrators in a self-referred outpatient setting: Treatment effects in relation to patient characteristics and treatment integrity.

Group cognitive behaviour therapy for intimate partner violence (IPV) perpetrators in a self-referred outpatient setting: Treatment effects in relation to patient characteristics and treatment integrity. - Not losing it anymore.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50752

Enrollment

180

Registered

2017-12-06

Start date

2018-01-31

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aggression Impulse control disorder

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: General study: Male Age 18 to 65 Aggression problems Self-referred treatmentPart of the study (stress and cognitive bias): Age 18 to 45 No medical coronary conditionPartners: Age 18 years or older In an intimatie relationship with patientditTrail

Exclusion criteria

Exclusion criteria: Aggression occurs exclusively in relation to substance abuse Severe psychopathology, for example, psychosis Moderate to severe intellectual disability Psychopathy is a contra-indication for group treatment, individual NMDHL treatment can be indicated (thus, psychopathic patients are excluded) Autism as primary diagnosis.Partners: Moderate to severe intellectual disability á*BBá*

Design outcomes

Primary

Measure	Time frame
The main study parameter is change in the frequency and severity of aggressive behaviour after NMDHL treatment. Aggressive behaviour will be evaluated by pre- and post-therapy administration of two self-report questionnaires and one partner questionnaire. Predictors that are hypothesised to be of influence on treatment effect are offender subtype, psychiatric co-morbidity, personality traits, stress reactivity, cognitive bias, motivation and treatment integrity. Offender subtype, psychiatric co-morbidity, personality traits, motivation and treatment integrity are assessed by self-report measures, a researcher-rated risk assessment instrument B-SAFER, semi-structured interview, and audiotaping sessions. Stress response is measured by cortisol level and a-amylase level before and after a stress induction test MAST. Social-cognitive bias is measured by FaceGen Modeller test.	—

Measure

Time frame

The main study parameter is change in the frequency and severity of aggressive behaviour after NMDHL treatment. Aggressive behaviour will be evaluated by pre- and post-therapy administration of two self-report questionnaires and one partner questionnaire. Predictors that are hypothesised to be of influence on treatment effect are offender subtype, psychiatric co-morbidity, personality traits, stress reactivity, cognitive bias, motivation and treatment integrity. Offender subtype, psychiatric co-morbidity, personality traits, motivation and treatment integrity are assessed by self-report measures, a researcher-rated risk assessment instrument B-SAFER, semi-structured interview, and audiotaping sessions. Stress response is measured by cortisol level and a-amylase level before and after a stress induction test MAST. Social-cognitive bias is measured by FaceGen Modeller test.

—

Secondary

Measure	Time frame
Treatment integrity of NMDHL treatment will be assessed. In order to score treatment integrity an intervention checklist will be developed. NMDHL treatment sessions are being audiotaped and coded by means of the intervention checklist. The intervention checklist concerns protocol adherence as well as non-specific therapeutic techniques.	—

Countries

Netherlands

Outcome results